spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  LEO Pharma 

 HSMN NewsFeed - 23 Apr 2024
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jun 2021
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 18 Jan 2021
Valeo Pharma Announces Major Addition to its Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2020
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2020
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
Biopharmaceuticals Regulatory Product Launch
 HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Aug 2019
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 2 Apr 2019
Perrigo Announces Patent Litigation Settlement for the Generic Version of Finacea(R) Foam, 15%
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Apr 2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 23 Jun 2017
LEO Pharma Appoints Chris Posner to Lead US Business
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 9 Jun 2017
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints David A. Spiegel as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints Roy Prieb as Chief Operating Officer and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Mar 2016
LEO Pharma Receives Scientific Approval of Enstilar(R) for the Treatment of Psoriasis in EU
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Nov 2015
LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2012
LEO Pharma Announces That Picato(R) (ingenol mebutate) gel has Been Approved by US FDA for Once-Daily, 2 or 3 day Treatment of Actinic Keratoses
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 25 Jan 2012
FDA Approves Picato(R) (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
Biopharmaceuticals Drug Delivery Dermatology FDA
 HSMN NewsFeed - 21 Mar 2011
Lithera Announces the Appointment of George W. Mahaffey as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2008
Dr. Michael Beckert Steps Down as EVP and CMO of LifeCycle Pharma Effective December 31, 2008
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2008
KaloBios Strengthens Development Expertise With Additions to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
GTC Obtains FDA Orphan Drug Designation For ATryn(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Sep 2007
GTC Obtains FDA Fast Track Designation for ATryn(R) and Permission to Submit a Rolling BLA
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jan 2007
ATryn(R) Market Authorization Transferred To LEO Pharma A/S
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
GTC Biotherapeutics and LFB Biotechnologies Enter Strategic Collaboration for Recombinant Plasma Proteins and Monoclonal Antibodies
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2006
ATryn(R) Receives CHMP Recommendation to Grant Market Authorization
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
LEO Pharma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.